SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.
Jul 22nd, 2022 23:02 EST
NEW YORK, July 22, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX), in connection with the Company's proposed merger with ARS Pharmaceuticals, Inc. ("ARS"). Under the terms of the merger agreement, assuming that the Company's net cash at closing is $240 million, Silverback equity holders are expected to own only approximately 37% of the combined company and pre-merger ARS equity holders are expected to own approximately 63% of the combined company.
If you own Silverback shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Weiss Law is investigating whether (i) Silverback's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the percentage of ownership is fair to Silverback's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE Weiss Law